HilleVax, Inc. (HLVX)
$2.09+0.00%Close
BUYBULL · day 18
Key stats
- Market cap
- $105M
- Beta
- 0.77
- P/E (TTM)
- -0.70
- 1W
- +0.00%
- 1M
- +1.46%
- vs SPY 1W
- +0.98%
- vs SPY 1M
- -0.41%
Industry peers
FMP comparable companies · ranked by market cap
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS & VALIDATION
[SCORES & PROFILE]
- FUND
- 17
- VALUE
- 30
- GROWTH
- 45
- GARP
- 6
- TYPE
- Value / Recovery (blended)
Composite of Value · Growth · GARP
ROIC-42.1%
REV YoY-
ROE-70.1%
EPS YoY-
ROA-76.4%
GROSS0
OP0
NET0
[VALUATION]
P/E TTM-0.70
P/E FWD-
SECTOR PE20.48
INDUSTRY PE13.99
P/B0.66
P/FCF-
EV/EBITDA0.16
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E15.87
ALTMAN Z-
CURR RATIO10.84
ND/EBITDA-
BETA0.77
[BEST COMBO]VALIDATED · V5
ENTER · HOLD · EXIT · WAITOne next-open action from five signal families, published only when the held-out edge survives 20 bps costs.
Today's action with its out-of-fold profit factor, trade count and family votes.
[WHITE ARROW]FULL HISTORY
BUY
Directional consensus stays BUY or SELL until the model reverses; trades fill next session open.
LOW CONFIDENCE · 13/20
PROFIT FACTOR0.4
TRADES13
[REGIME]FULL HISTORY
BULL
BULL or RECOVERY stays invested; BEAR or CRISIS exits at the next session open.
Profit factor and trade count for holding this symbol only in BULL or RECOVERY.
[EXHAUSTION]NOW
Whether buyers or sellers are stretched today, the latest release and its strength.
Company news
Loading headlines…
FAQ
- What is LOPJLB’s current signal on HLVX?
- LOPJLB’s latest quantitative signal on HilleVax, Inc. (HLVX) is BUY in a BULL regime. Signals are updated daily.
- What market regime is HLVX in?
- HilleVax, Inc. (HLVX) is currently classified in the BULL HMM market regime on LOPJLB.
- What does HilleVax, Inc. (HLVX) do?
- HilleVax, Inc. is a clinical-stage biopharmaceutical enterprise specializing in the creation and market introduction of innovative vaccines. The company's lead investigational product is HIL-214, a vaccine candidate utilizing virus-like particles, which aims to prevent moderate-to-severe acute gastroenteritis resulting from norovirus infections. Its corporate headquarters are located in Boston,…